Susquehanna International Group’s Janux Therapeutics JANX Stock Holding History

Susquehanna International Group’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.04M	Buy	362,500 +62,000	+21%	+$850K	﹤0.01%	4209
2025 Q4	$4.15M	Buy	300,500 +133,400	+80%	+$3.14M	﹤0.01%	4326
2025 Q3	$4.08M	Buy	167,100 +64,800	+63%	+$1.58M	﹤0.01%	4434
2025 Q2	$2.36M	Buy	102,300 +14,700	+17%	+$387K	﹤0.01%	5436
2025 Q1	$2.37M	Sell	87,600 -135,500	-61%	-$5.11M	﹤0.01%	5163
2024 Q4	$11.9M	Buy	223,100 +104,100	+87%	+$5.51M	﹤0.01%	2438
2024 Q3	$5.41M	Buy	119,000 +50,600	+74%	+$2.2M	﹤0.01%	3476
2024 Q2	$2.87M	Sell	68,400 -21,200	-24%	-$995K	﹤0.01%	4403
2024 Q1	$3.37M	Buy	+89,600	New	+$1.95M	﹤0.01%	4283

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Susquehanna International Group's JANX Position: Q1 2026 in Review

Susquehanna International Group increased its Janux Therapeutics (JANX) stake by 238% in Q1 2026, buying an estimated $1.15M and bringing the position to 119,055 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #6606.

Susquehanna International Group first reported a position in JANX in Q1 2023 and has held it in 10 quarters since. The position peaked at $9.96M in Q1 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

Susquehanna International Group held 119,055 shares of Janux Therapeutics worth $1.65M as of Q1 2026.
Susquehanna International Group bought 83,818 Janux Therapeutics shares in Q1 2026, an estimated $1.15M.
Janux Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6606 holding.
Susquehanna International Group first reported a position in Janux Therapeutics in Q1 2023 and has held it in 10 quarters since.
Susquehanna International Group's Janux Therapeutics position peaked at $9.96M in Q1 2025.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.